[go: up one dir, main page]

MX2011008213A - Preparaciones farmaceuticas transdermicas. - Google Patents

Preparaciones farmaceuticas transdermicas.

Info

Publication number
MX2011008213A
MX2011008213A MX2011008213A MX2011008213A MX2011008213A MX 2011008213 A MX2011008213 A MX 2011008213A MX 2011008213 A MX2011008213 A MX 2011008213A MX 2011008213 A MX2011008213 A MX 2011008213A MX 2011008213 A MX2011008213 A MX 2011008213A
Authority
MX
Mexico
Prior art keywords
transdermal pharmaceutical
pharmaceutical preparations
bioavailability
dispersed
gel
Prior art date
Application number
MX2011008213A
Other languages
English (en)
Inventor
Endre Mikulasik
Patrik Fazekas
Original Assignee
Egis Gyogyszergyar Nylvanosan Muekoedoe Reszvenytarsasag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyogyszergyar Nylvanosan Muekoedoe Reszvenytarsasag filed Critical Egis Gyogyszergyar Nylvanosan Muekoedoe Reszvenytarsasag
Publication of MX2011008213A publication Critical patent/MX2011008213A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

La presente invención se refiere a una preparación farmacéutica transdérmica semisólida que tiene estabilidad y biodisponibilidad mejoradas, donde las partículas están recubiertas por un componente volátil de aceite de silicio y la suspensión así obtenida se dispersa en una base de gel o crema.
MX2011008213A 2009-02-06 2010-02-05 Preparaciones farmaceuticas transdermicas. MX2011008213A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0900072A HUP0900072A2 (hu) 2009-02-06 2009-02-06 Transzdermális gyógyszerkészítmények
PCT/HU2010/000015 WO2010089617A2 (en) 2009-02-06 2010-02-05 Transdermal pharmaceutical preparations

Publications (1)

Publication Number Publication Date
MX2011008213A true MX2011008213A (es) 2011-09-28

Family

ID=89988766

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008213A MX2011008213A (es) 2009-02-06 2010-02-05 Preparaciones farmaceuticas transdermicas.

Country Status (18)

Country Link
US (1) US20120024743A1 (es)
EP (1) EP2393479A2 (es)
JP (1) JP2012517414A (es)
KR (1) KR20110120304A (es)
CN (2) CN103349643A (es)
AU (1) AU2010212158A1 (es)
BR (1) BRPI1005433A2 (es)
CA (1) CA2751633A1 (es)
CL (1) CL2011001875A1 (es)
EA (1) EA023502B1 (es)
HU (1) HUP0900072A2 (es)
IL (1) IL214402A0 (es)
MX (1) MX2011008213A (es)
NZ (1) NZ594618A (es)
PE (1) PE20120584A1 (es)
UA (1) UA107563C2 (es)
WO (1) WO2010089617A2 (es)
ZA (1) ZA201105662B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065533A1 (en) * 2011-01-24 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles for dermal and systemic delivery of drugs
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) * 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
JP5630679B1 (ja) * 2013-09-08 2014-11-26 株式会社Ｅ・テック 揮発性消毒剤、揮発性消毒剤の製造方法
EP3110427A4 (en) * 2014-02-24 2018-05-30 Urigen Pharmaceuticals, Inc. Compositions of pentosan polysulfate salts for oral administration and methods of use
MX2020002288A (es) 2016-08-31 2020-07-14 Oji Holdings Corp Metodo de produccion para xilooligosacarido acido y xilooligosacarido acido.
JP6225321B1 (ja) 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
JP6555431B2 (ja) * 2017-05-31 2019-08-07 王子ホールディングス株式会社 保湿外用剤
FI3683242T3 (fi) 2017-09-12 2025-01-15 Oji Holdings Corp Pentosaanipolysulfaatti ja menetelmä pentosaanipolysulfaatin valmistamiseksi
WO2019124363A1 (ja) 2017-12-20 2019-06-27 王子ホールディングス株式会社 ポリ硫酸ペントサン及びポリ硫酸ペントサンを含む医薬
RU2704623C1 (ru) * 2018-12-07 2019-10-30 Общество с ограниченной ответственностью "Научно-производственное объединение "Ликом" Перевязочное средство на биополимерной основе
TW202202129A (zh) * 2020-07-10 2022-01-16 大陸商江蘇恒瑞醫藥股份有限公司 含麻醉藥物活性成分的透皮製劑及其製備方法
CN115475224B (zh) * 2022-08-31 2023-11-28 中国人民解放军空军特色医学中心 一种用于治疗冻疮的药膏及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1141094B (it) 1979-12-03 1986-10-01 Gen Electric Emulsioni di siliconi volantili e acqua e loro metodo di preparazione ed uso
DE3010572C2 (de) 1980-03-19 1982-05-06 Süess, Hans R., Dr., Starrkirch Hautpflege- und Hautschutzpräparate
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US5336692A (en) 1990-06-28 1994-08-09 Medicis Pharmaceutical Corporation Ointment base and method of use
FR2709131B1 (fr) * 1993-08-18 1995-11-10 Cilag Laboratoire Dispositif de distribution d'une substance thérapeutique ou cosmétique dont le véhicule inerte est un polydiorganosiloxane volatil, et composition destinée à être utilisée dans le dispositif.
DE19837850C1 (de) 1998-08-20 2000-01-05 Wacker Chemie Gmbh Mischungen flüchtiger linearer Siloxane, Verfahren zu ihrer Herstellung sowie diese enthaltenden kosmetischen Formulierungen
IT1302275B1 (it) 1998-09-25 2000-09-05 Giorgio Panin Formulazione di gel idrofobo a base di vitamina e acetato perapplicazione topica.
EP1472263B1 (de) 2001-11-13 2006-08-30 GE Bayer Silicones GmbH & Co. KG Verwendung von siloxanen als verdampfbare träger
CA2543577A1 (en) 2003-11-21 2005-06-16 Galderma Research & Development, S.N.C. Sprayable composition for the administration of vitamin d derivatives
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
WO2006138035A1 (en) * 2005-06-13 2006-12-28 Dow Corning Corporation Vehicle for the delivery of topical lipid soluble pharmaceutical agents
US20070036731A1 (en) * 2005-08-13 2007-02-15 Collegium Pharmaceutical, Inc. Topical Delivery with a Carrier Fluid
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility

Also Published As

Publication number Publication date
US20120024743A1 (en) 2012-02-02
UA107563C2 (uk) 2015-01-26
WO2010089617A2 (en) 2010-08-12
IL214402A0 (en) 2011-09-27
EA023502B1 (ru) 2016-06-30
AU2010212158A1 (en) 2011-09-08
CN103349643A (zh) 2013-10-16
EA201190134A1 (ru) 2012-02-28
PE20120584A1 (es) 2012-05-23
CN102573793A (zh) 2012-07-11
ZA201105662B (en) 2012-10-31
WO2010089617A3 (en) 2011-06-16
JP2012517414A (ja) 2012-08-02
HUP0900072A2 (hu) 2010-09-28
CA2751633A1 (en) 2010-08-12
CL2011001875A1 (es) 2012-07-13
NZ594618A (en) 2014-01-31
EP2393479A2 (en) 2011-12-14
KR20110120304A (ko) 2011-11-03
HU0900072D0 (en) 2009-03-30
BRPI1005433A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
MX2011008213A (es) Preparaciones farmaceuticas transdermicas.
UA104005C2 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
WO2013177421A3 (en) Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same
MX2020000984A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
EA201270722A1 (ru) Формы рифаксимина и их применение
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
WO2011135461A3 (en) Clay compositions
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
WO2012174158A3 (en) Administration of benzodiazepine
AU2016219704A1 (en) Anti-Notch1 antibodies
MX342257B (es) Derivados y análogos de oxaspiro [2.5] octano.
EP2816035A3 (en) Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2012003501A3 (en) Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EP3278799A4 (en) Docetaxol albumin nanoparticle pharmaceutical composition, preparation method therefor and use thereof
PH12016500924A1 (en) Anti-cancer agents and preparation thereof
EA201400444A1 (ru) Производные 2-оксопиперидинила
MX371209B (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
MY164822A (en) Pharmaceutical compositions of carotenoid
EA201590752A1 (ru) Препараты производных пиримидиндиона
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
TN2010000334A1 (en) Semisolid pharmaceutical formulations
WO2014044869A3 (de) Medizinisches präparat umfassend einen träger mit polyhexanid oder octenidin
WO2013102195A8 (en) Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal